Ricardo G. Pacheco, M.D.

Partner

BSG Pharmaceuticals

Ricardo G. Pacheco, M.D.

Dr. Ricardo Gaminha Pacheco, MD | MFPM & FFPM | CMD | MBA | BCMAS | MPHc holds a Master in Medicine Degree, from Charles University in Prague, Czech Republic, is a specialist in Pharmaceutical Medicine from the Faculty of Pharmaceutical Medicine, London, UK & the European Center of Pharmaceutical Medicine, University of Basel, Switzerland, soon to become specialist in Public Health and has a Professional Certification in Medicines Development from King’s College London & IFAPP – International Federation of Associations of Pharmaceutical Physicians & Pharmaceutical Medicine.

More recently he has completed an Executive MBA from The Lisbon MBA - Católica | NOVA, Lisbon, Portugal in collaboration with MIT Sloan, Cambridge, Massachusetts, USA and obtained a Professional Certificate in Entrepreneurship from MIT Sloan School of Management, Cambridge, Massachusetts, USA, as well as, a Board Certified Medical Affairs Specialist degree from the Accreditation Council of Medical Affairs, USA, successfully completed the Venture Deals Course from Kauffman Fellows & Techstars, USA and had a Postgraduate Degree in Human Genetics & Genomic Medicine from NOVA Medical School, Lisbon, Portugal. He is currently completing a Master of Public Health from the London School of Hygiene & Tropical Medicine and Said's Business School, Oxford's Entrepreneurship Venture Finance Programme.

Dr. Ricardo began his professional activity by practicing medicine in the Portuguese National Health System and in Private Health Institutions at José de Mello Saúde, and later decided to dedicate himself to Healthcare Innovation, Clinical Research, Pharmacology & Medicines Development, Health Management and Leadership, moving to the Pharmaceutical & Biotech Industry as a Physician Executive, where in the last 11-12 years he has held multiple roles of increasing responsibility and leadership levels at National, European and Global levels in worldwide renown Pharmaceutical and Biotechnology companies such as Vemedia, UCB, Schulke & Mayr | AirLiquide Healthcare, Nycomed (now Takeda Pharmaceuticals), Novartis, AstraZeneca and Roche | Genentech.

More recently, he kickstarted his entrepreneurial and investor journey, being currently Partner and Chief Strategy Officer & Business Development Head at BSG Pharmaceuticals and Co-Founder of NeuroSoV: an early-stage Biopharmaceutical venture focused on developing therapies for neurodegenerative disorders, with its first lead candidate under development for Parkinson’s Disease. Moreover, he is a Venture Scout and Angel Investor of promising disruptive start-ups aiming to revolutionize healthcare.

Dr. Ricardo is a invited lecturer at the i3du Medicines and Pharmaceutical Innovation Doctoral PhD Program at the Faculty of Pharmacy, University of Lisbon, Portugal & invited Professor for the Master of Medicine Degree at Faculty of Health Sciences, University of Beira Interior, Portugal and a Life-Sciences | Healthcare Consultant for multiple start-ups/SMEs, incubators/accelerators in the health sector and networks of Business Angels, Venture Capital & Private Equity firms.

He is a Global Public Health enthusiast on the path to reimagine healthcare through life-sciences innovation, exploring preventive, personalized & Integrative healthcare models of the future and is interested in AI, Technology, Aging & Longevity Medicine, Neuroscience, Cancer, Genomics, Regenerative, Aerospace/nautical and Pharmaceutical Medicine research.

He is part of a select community of executives on McKinsey's Online Executive Panel, Global Thinkers 360º, Fight Cancer Global Leadership Panel & World Future Society Visionary Member, BGI | Building Global Innovators Startup Mentor, Pharma Top Talent Ambassador & was recently nominated for the Global Health | Pharma Life Sciences Award 2020.

His expertise within Life-Sciences Industry together with his entrepreneurial drive and mindset has allowed him to deliver continuous value to the start-ups he has been mentoring and the incubators/accelerators and Venture Capital Funds he collaborates with.